...
首页> 外文期刊>Journal of Basic and Clinical Pharmacy >Evaluation of Drug-Drug Interactions Among Chronic Kidney Disease Patients of Nephrology Unit in the University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu State
【24h】

Evaluation of Drug-Drug Interactions Among Chronic Kidney Disease Patients of Nephrology Unit in the University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu State

机译:在埃努古州伊图库-奥扎拉的尼日利亚大学教学医院,肾病科的慢性肾脏病患者中药物相互作用的评估

获取原文
           

摘要

Context: Chronic kidney disease (CKD) patients are at high risk of drug-drug interactions (DDIs) that may require dose adjustments or the avoidance of drug combinations. Aim: To evaluate DDIs among chronic kidney disease patients of nephrology unit in the University of Nigeria Teaching Hospital (UNTH), Enugu in South-East Nigeria. Settings and Design: This study was a retrospective review of CKD patients who received treatment at the nephrology unit of UNTH between January 2004 and December 2014. Methods and Materials: The drug-drug interactions (DDIs) of the prescribed drugs were classified using the Medscape drug interaction checker. Statistical Analysis used the data were analyzed using the Statistical Package for Social Sciences (SPSS) for Windows version 16.0 (SPSS Inc, Version 16.0, Chicago, USA). The predictors of the DDIs were explored through linear regression with number of DDIs as the dependent variable. Results: A total of 898 DDIs were identified from the folders of the 169 CKD patients that were eligible. Majority were above 50 years old and in renal disease stage 4 or 5. Furosemide, lisinopril and amlodipine were the most frequently prescribed drugs and had the greatest likelihood for nephrotoxicity. The number of medications and hypertension (as co-morbidity) were the independent predictors of DDIs among the patients. Majority of the DDIs (64.14%) were significant. The most common interactions were between lisinopril and furosemide; furosemide and calcium carbonate; lisinopril and calcium carbonate. Conclusion: The prevalence of significant DDIs was high among the renal patients. The major determinants of the DDIs were the number of medications and the presence of hypertension as co-morbidity.
机译:背景:慢性肾脏病(CKD)患者处于药物相互作用(DDI)的高风险中,可能需要调整剂量或避免药物组合。目的:评估尼日利亚东南部埃努古(Enugu)的尼日利亚大学教学医院(UNTH)肾脏病科慢性肾脏病患者的DDIs。设置和设计:本研究是对在2004年1月至2014年12月期间在UNTH肾脏病科接受治疗的CKD患者的回顾性回顾。方法和材料:使用Medscape对处方药的药物相互作用(DDI)进行分类药物相互作用检查器。统计分析使用的数据是使用Windows版本16.0(SPSS Inc,版本16.0,美国芝加哥)的社会科学统计软件包(SPSS)进行分析的。通过线性回归以DDI的数量作为因变量来探索DDI的预测变量。结果:从169名符合条件的CKD患者的资料夹中总共识别出898个DDI。多数年龄超过50岁,处于肾病第4或第5期。速尿,赖诺普利和氨氯地平是最常用的处方药,并且发生肾毒性的可能性最大。药物数量和高血压(作为合并症)是患者中DDI的独立预测因子。 DDI的大多数(64.14%)是重要的。最常见的相互作用是赖诺普利和速尿之间的相互作用。速尿和碳酸钙;赖诺普利和碳酸钙。结论:肾病患者中重要DDI的发生率很高。 DDI的主要决定因素是药物的数量和高血压是否是合并症。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号